Drug Discovery
ByDespite Geopolitical Tensions, U.S.–China Biotech Interdependence Remains Central
23 January 2026 Executive Summary Industry reports continue to underscore the deep interdependence between U.S. and Chinese biotech…
Are China’s Innovation and Cost Advantages Redrawing Global Biopharma Competition?
23 January 2026 Executive Summary Competitive dynamics across global biopharma in 2026 are being fundamentally reshaped by China’s…
Is China Outpacing the Global Biopharma Cycle? Innovation and Deal Momentum Accelerate
23 January 2026 Executive Summary China’s biopharma sector is continuing to advance at remarkable speed, with recent analyses…
Is China Becoming a Power Center for AI-Led Drug Discovery? Insilico Medicine Strikes $66 Million NLRP3 Licensing Deal
23 January 2026 Executive Summary Artificial-intelligence-driven drug developer Insilico Medicine has entered into a $66 million licensing agreement…
Will Johnson & Johnson’s 2025 Earnings Reinforce Confidence in Its Pharma-Led Growth Engine?
Late January 2026 | Full-Year 2025 Earnings Preview | Diversified Pharma Outlook Johnson & Johnson (J&J) is set…
Can Pfizer’s 2025 Earnings Reignite Confidence in Its Post-COVID Portfolio and Late-Stage Pipeline?
Late January 2026 | Full-Year 2025 Earnings Preview | Big Pharma Strategy Reset Pfizer is set to report…
